J Korean Ophthalmol Soc > Volume 49(4); 2008 > Article
Journal of the Korean Ophthalmological Society 2008;49(4):696-700.
DOI: https://doi.org/10.3341/jkos.2008.49.4.696    Published online April 15, 2008.
Intraviteal Bevacizumab (Avastin(R)) Injection for the Treatment of Early-Stage Neovascular Glaucoma.
Hyosung Maeng, Jinchul Kim, Changwon Kee
Department of Ophthalmology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. cwkee@skku.edu
초기 신생혈관 녹내장에서 Bevacizumab (Avastin®)를 이용한 치료 1예
맹효성ㆍ김진철ㆍ기창원
Department of Ophthalmology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
Abstract
PURPOSE
This case is conducted to assess the short term safety and efficacy of intravitreal bevacizumab injection in patient with early stage of the neovascular glaucoma (NVG) without peripheral anterior synechiae. CASE SUMMARY: A 66 year old patient with a history of proliferative diabetic retinopathy presented with neovascularization of the iris and the angle and high intraocular pressure of 30 mmHg. The patient received a single injection of bevacizumab (1.25 mg /0.05 mg) intravitreally. The visual acuity (VA), intraocular pressure (IOP), regression of the iris and the angle neovascularization were measured up to the twenty ninth week after injection. Regression of the iris and angle neovascularization were confirmed from the second week after injection. The visual acuity had continued stable and the IOP had been controlled from 30 mmHg to 20 mmHg from fifth week without the need for topical antiglaucoma medications until the twenty ninth week. CONCLUSIONS: Bevacizumab may be an effective medication for the treatment of neovascular glaucoma. Bevacizumab seems to be a useful adjunct or an advantageous treatment option to panretinal photocoagulation in the treatment of neovascular glaucoma.
Key Words: Intravitreal bevacizumab injection;Early-stage neovascular glaucoma;Panretinal photocoagulation


ABOUT
BROWSE ARTICLES
EDITORIAL POLICY
FOR CONTRIBUTORS
Editorial Office
SKY 1004 Building #701
50-1 Jungnim-ro, Jung-gu, Seoul 04508, Korea
Tel: +82-2-583-6520    Fax: +82-2-583-6521    E-mail: kos08@ophthalmology.org                

Copyright © 2022 by Korean Ophthalmological Society.

Developed in M2PI

Close layer
prev next